enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Sells $717,810.00 in Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the sale, the insider now owns 3,036,153 shares in the company, valued at $45,542,295. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The shares were sold at an average price of $15.01, for a total value of $68,670.75.

enGene Stock Performance

NASDAQ:ENGN opened at $14.75 on Thursday. The firm’s 50-day simple moving average is $16.23. enGene Holdings Inc. has a fifty-two week low of $6.69 and a fifty-two week high of $43.00.

Institutional Investors Weigh In On enGene

Institutional investors have recently modified their holdings of the stock. Fcpm Iii Services B.V. purchased a new stake in shares of enGene during the 4th quarter worth about $80,097,000. Omega Fund Management LLC bought a new position in enGene during the fourth quarter valued at approximately $10,441,000. BVF Inc. IL acquired a new stake in enGene in the fourth quarter valued at approximately $20,777,000. Finally, Vivo Capital LLC bought a new stake in enGene in the fourth quarter worth approximately $6,264,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on ENGN shares. Leerink Partnrs restated an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Morgan Stanley initiated coverage on shares of enGene in a research note on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective on the stock. Wells Fargo & Company started coverage on shares of enGene in a research report on Monday. They issued an “overweight” rating and a $30.00 target price for the company. SVB Leerink initiated coverage on enGene in a research note on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price objective for the company. Finally, UBS Group began coverage on enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $34.40.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.